CT1190B for large B-cell lymphoma that has returned or not responded to treatment
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new treatment called CT1190B for people with large B-cell lymphoma that has come back or hasn't responded to at least two prior treatments. The goal is to see if this treatment can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a type of large B-cell lymphoma, such as diffuse large B-cell lymphoma or transformed follicular lymphoma.
- You have already tried at least two standard treatments, and your cancer has either returned or did not respond.
- You have at least one measurable tumor that can be seen on a CT or MRI scan.
- You are generally well enough to carry out daily activities (ECOG score 0 or 1).
- You are willing to use effective birth control during and for one year after the study, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy designed to target and destroy cancer cells that have the CD19 marker. It may help people with large B-cell lymphoma that has relapsed or not responded to standard treatments.
This study tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that came back or did not improve after other treatments. The therapy uses your own immune cells to fight the cancer, and the study aims to see if it is safe and effective.
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
This trial tests a new type of CAR-T cell therapy that may be better at remembering and attacking lymphoma cells. It is for people with large B-cell lymphoma that has not responded to standard treatments or has come back.
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
Hear when a new Large B-Cell Lymphoma (LBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.